There is an ever-growing need to control antibiotic-resistance owing to alarming resistance to commonly available antimicrobial agents for which contemporary and alternative approaches are being explored. The present study assessed the antibacterial activity of bacteriocins from lactic acid bacteria (LAB) from lesser known traditionally fermented products of India for their synergistic potential with common antibiotics against clinical b-lactamases producing pathogens. A total of 84 isolates of LAB were screened for their antibacterial efficacy against Streptococcus pyogenes, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae and Bacillus cereus as well as against clinical pathogens harbouring b-lactamase genes such as bla CTX-M, bla VIM, bla IMP , bla SHV and bla NDM . Synergistic activity of bacteriocins were determined in combination with antibiotics namely, cefotaxime, polymyxin B, imipenem and tigecycline.
Introduction
Nosocomial infections have become a prime concern in the past few decades. A nosocomial can be defined as an infection acquired in hospital by a patient admitted for a reason other than that infection (Ducel et al. 2002) Microorganisms such as Staphylococcus aureus, coagulase-negative staphylococci, enterococci and those belonging to the Enterobacteriaceae family are found to be the source of such hospital acquired infections. The upsurge in bacterial resistance towards antibiotics and appearance of multidrug-resistant (MDR) microorganisms has been an important factor for increasing nosocomial infections. Pathogens responsible for such infections are found to be resistant to single or multiple antibiotics, which demands development of new antimicrobials. In the recent past, variety of compounds possessing antimicrobial property such as plant-derived compounds, bacteriophages and potential bactericidal compounds from bacteria have been investigated for their activity against such MDR pathogenic strains Sulakvelidze et al. 2001) . Antimicrobial peptides known as bacteriocins have attracted attention in this regard in the recent past (Rapsang et al. 2011) .
Bacteriocins from lactic acid bacteria (LAB) are ribosomally synthesized antimicrobial peptides or proteins which possess inhibitory activity towards wide range of pathogens (De Vuyst & Leroy 2007) . LAB are non-pathogenic probiotic microorganisms, present in normal flora which exert positive influence in host physiology and belong to the genus Lactobacillus, Enterococcus, Pediococcus and Bifidobacterium (Martha et al. 2001; Ouwehand et al. 2002) . Studies have established the inhibitory potential of probiotics against pathogenic strains of Salmonella, Escherichia, Staphylococcus, Bacillus, Klebsiella and Listeria (Drago et al. 1997; Rapsang and Joshi 2012; Rapsang et al. 2013) . These probiotics produce bacteriocins and bacteriocin-like molecules, which display a wide range of antimicrobial activity against Gram-positive and Gram-negative bacteria (De Vuyst & Leroy 2007) .
With the evolution of bacterial resistance to vast range of antibiotics in humans, such probiotic therapy appears to be futuristic alternative to prevent dissemination of MDR pathogens. The inherent properties such as low toxicity, potency, availability of broad and narrow spectrum peptides of bacteriocins imply that they are viable alternatives to antibiotics (Cotter et al. 2013) . Studies on lantibiotics such as nisin, lacticin 3147 belonging to the class I bacteriocin, have shown prominent activity against Streptococcus pneumoniae, staphylococci including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (Piper et al. 2009) . Bacteriocin produced by particular strain of Enterococcus faecium against MDR bacterial species have been reported (Ali et al. 2012) . The effectiveness of individual bacteriocins from potential LAB strains could be further enhanced through combination with other antimicrobials and commercially available antibiotics. Studies have reported the synergistic activity of nisin with antibiotics polymyxin E and clarithromycin against Pseudomonas aeruginosa (Giacometti et al. 2000) and with ramoplanin and other noneblactam antibiotics against various strains of MRSA and vancomycinresistant enterococci (Giacometti et al. 2000; Brumfitt et al. 2002) .
Large variety of traditionally fermented products produced and consumed by tribals of Northeast India are rich sources of LAB (Thapa et al. 2004; Tamang et al. 2005; Jeyaram et al. 2010; Rapsang et al. 2011; Taheri et al. 2011) and can be good source of probiotics and bacteriocins. Bacteriocin like compounds from LAB associated with traditional fermented foods to control the propagation of clinical and food borne pathogens with probiotic therapy appears to be an innovative alternative to reduce dissemination of pathogens.
The present study was aimed to screen bacteriocin-producing LAB from two traditionally fermented products Tungtap (fish product) and Tungrymbai (soybean product) and determine their antibacterial activity alone and in combination with commercially available antimicrobial agents against MDR pathogens and clinical isolates.
Materials and Methods

Sample collection
Fifteen samples of Tungtap, a traditionally fermented Puntius species ( Figure S1 ) and eight samples of Tungrymbai, a traditionally fermented soybean ( Figure S2 ) were collected (during 2012e2015) from retail markets of Northeast India in sterile containers and were transported aseptically to the laboratory for analysis within 24 h.
Isolation of LAB
The samples were homogenized using mortar and pestle. Ten grammes of the homogenised sample was then blended in 90 mL of 0.85% (w/v NaCl) physiological saline. The total viable LAB counts in each sample was analysed by spread plating the serially diluted samples on de Man, Rogosa and Sharpe (MRS) agar (HiMedia, Mumbai, India). The inoculated plates were incubated at 37 C for 48e72 h for isolation of LAB (Rapsang & Joshi 2012 (Kumarasamy et al. 2010; Upadhaya and Joshi 2015) . The sensitivity patterns of these organisms against standard antibiotics were previously tested using CLSI guidelines 2013 (Wayne 2013).
Screening of LAB for antimicrobial activity
Agar spot assay test (Schillinger & Lücke 1989) was carried out in triplicate to screen the LAB isolates for their antimicrobial activity. Each of the LAB isolate was grown in MRS broth for 24 h at 37 C. The cultures were then adjusted 1.5 Â 10 8 CFU/mL. Ten microlitres of the cell suspension from each isolate was spotted onto the surface of MRS agar plates and incubated at 37 C for 24 h. After the incubation period, the colonies were then overlaid with 10 mL of Brain Heart Infusion (HiMedia, Mumbai, India) soft agar containing 10 7 CFU/mL of indicator organisms (S. pyogenes, E. faecalis, E. coli, K. pneumoniae and B. cereus). The plates were incubated overnight at 37 C before recording the diameter of inhibition zones.
Bacteriocin production and activity
The bacterial colonies showing antibacterial activity were selected as potential bacteriocin producers. The colonies were subcultured in 50 mL MRS broth and incubated for 24 h at 37 C in a rotary shaker with agitation at 150 rpm. The cultures were centrifuged at 10,000 rpm for 30 min at 4 C. A portion of the cell-free supernatant was neutralized with 1M NaOH (pH 6.8 ± 0.2) to rule out possible inhibition effects due to organic acids and filtered sterilized through 0.22 mm membrane (Puradisc 25mm, India). To determine the activity of the supernatant, agar well-diffusion method was performed in triplicate . Müller-Hinton agar (HiMedia, Mumbai, India) plates were swabbed with bacterial cell suspension of the indicator strains and clinical pathogens adjusted to 1.5 Â 10 8 CFU/mL. Five-millimetre diameter wells were cut in the agar plate using a sterile cork borer. Hundred microlitre aliquot of each supernatant was added to each well and the plates were incubated at 37 C for 24 h. After incubation, zones of inhibition around the wells were measured manually.
2.6. Physio-chemical characterization of inhibitory substances 2.6.1. Effect of enzymes Aliquots of 200 mL of the cell-free supernatant were treated with proteolytic enzymes such as catalase (2.6 U/mg), pepsin (16 U/mg), proteinase K (3 U/mg), pronase E (22 U/mg) and trypsin (15 U/mg). The assays were performed at a final concentration of 1 mg/mL and at pH 6.5, except for pepsin (pH 3.0). Treated samples were held at 37 C for 6 h. After the incubation process, samples were boiled at 100 C for 5 min to stop the reaction. Untreated cell-free supernatant was used as control. The antimicrobial activity of the treated and untreated supernatant was determined by agar well-diffusion assay following the above-mentioned protocol using the selected indicator strains.
Effect of temperature and different pH
To establish the effect of temperature on antibacterial activity, aliquots of 200 mL of the cell-free supernatant were heated at 60 C, 80 C and 100 C for 60 min and at 120 C for 15 min. Aliquots of 200 mL of the cell-free supernatant were adjusted to different pH from 2 to 10 with HCl (5 M) and NaOH (5 M) and incubated for 4 h at 30 C. The residual activity was tested as described previously.
Preparation of LAB extracts
To prepare the extracts, the LAB cultures were grown at 37 C for 48 h. Cell-free supernatant obtained by centrifuging the culture broth at 10,000 rpm for 30 min was concentrated in rotary evaporator for 3 h at 30 C. The weight of the concentrated sample was determined and re-suspended in 0.05 M potassium phosphate buffer (pH 7) to make desired concentration and stored at À20 C until further use.
Evaluation of synergistic effect
The efficacy of LAB bacteriocin extract alone and in combination with commercially available antibiotics polymyxin B, tigecycline, imipenem and cefotaxime (HiMedia, Mumbai, India) against the MDR clinical pathogens was determined by using disc diffusion method in triplicate. To study the combined effect of bacteriocin extract and antibiotics, 20 mL (2 mg) of the bacteriocin extract was added to the standard antibiotic disc which was placed on Müller-Hinton agar plates inoculated with the test organisms. For positive control, standard antibiotic discs were used. The plates were incubated overnight at 37 C and zones of inhibition were recorded. The increase in fold area was assessed by calculating the mean surface area of the zone of inhibition obtained by the antibiotic alone and in combination with the bacteriocin (Birla et al. 2009 ). The fold area increase for the antibiotics was calculated by the formula (
, where a and b are the zone of inhibition for antibiotic alone and antibiotic in combination with bacteriocin, respectively.
Determination of minimum inhibitory concentration
Minimum inhibitory concentration (MIC) of the LAB extracts was performed in triplicate using broth microdilution method (Nath & Joshi 2014) in 96 multiwell microtiter plates in triplicates. 0.5 McFarland standard suspension of the indicator bacteria and the clinical isolates were inoculated in Müller-Hinton broth medium. Fifty microlitres of the inoculum was added to appropriate wells containing 50 mL of bacteriocin extract of different LAB in different concentrations. The final concentrations of the extracts used to evaluate the antibacterial activity were in the range of 3.33e66.66 mg/mL. The 96-well plates were then sealed with parafilm and incubated in aseptic condition at 37 C for 18 h. One hour before the incubation period, 50 mL of 0.5% solution of 2,3,5-triphenyl tetrazolium chloride (Sigma, India) was added to the wells and the plates were incubated for another hour in dark conditions. The colourless tetrazolium salt was reduced to a red colour compound by biologically active organisms. The inhibition of growth can be detected when the solution in the well remains clear after the incubation with triphenyl tetrazolium chloride. The lowest concentration of each extract showing no visible growth was recorded as the MIC.
Identification of bacteriocin-producing LAB
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database of type strains in manually curated and validly published prokaryotic names at the EzTaxon 2.1 server (https://www. ezbiocloud.net/resources/16s_download) (Chun et al. 2007 ). Molecular Evolutionary Genetics Analysis software (MEGA version 6.0) (http://megasoftware.net/) was used for phylogenetic analyses (Tamura et al. 2007 ). The sequences retrieved from database were aligned with the studied isolates using Clustal W inbuilt with MEGA 6.0. To construct the phylogenetic tree, neighbour-joining method was used with 500 bootstrap replications to assess nodal support in the tree.
Results
3.1. Isolation of LAB, antibacterial activity, characterization of inhibitory substances and bacteriocin production A total of 84 isolates of LAB were obtained from the traditionally fermented products. Screening for the production of potential antimicrobial bacteriocin revealed 11 isolates (13.09%) inhibiting the growth of the indicator organisms and clinical isolates (Table 1; Figure 1 ).
The isolate LS5 showed the highest zone of inhibition (26 mm) against E. faecalis. E. coli was moderately inhibited by the bacteriocin with the highest zone of inhibition (23 mm) by the cell-free extract of the isolate LU11.
Of the 11 different MDR clinical pathogens tested, four bacteriocin-producing isolates (LS5, LS3, LU11 and LS6) exhibited antibacterial activity against all the clinical pathogens (Table 1; Figure 2 ). Among these, the isolates LS6 and LU11 showing high antibacterial activity against the tested indicator strains and clinical isolates were selected for further study.
Antibacterial activity of the cell-free supernatant showed no activity when treated with the proteolytic enzymes except pepsin. The inhibitory activity was not affected by the effect of catalase indicating that the growth inhibition was not due to hydrogen peroxide production ( Table 2 ). The cell-free supernatant was stable to heat treatment at 60 C and 80 C for 60 min. However, heating at 100 C and 121 C reduced the activity by 30%e50% ( Table 2 ). The antibacterial activity was also maintained stable over the pH range of 2e10 (Table 2) .
Synergistic effect of LAB extract with antibiotics
The effect of bacteriocin extract from the isolates LU11 and LS6 alone and in combination with antibiotics against the MDR clinical pathogens E. coli (GN9, IB9, GN13), K. pneumoniae KP7 and A. baumannii AB13775 revealed different inhibitory effects (Table 3) . The efficacy of polymyxin B and imipenem in combination with LU11 and LS6 extracts showed increased activity against all the strains of E. coli and K. pneumoniae. The bacteriocin extract of the isolate LU11 showed maximum increase in fold area of 1.086 with tigecycline against A. baumannii (Figure 3) . Similarly, LS6 extract showed the highest activity in combination with tigecycline against E. coli GN9 with an increase in fold area of 1.60. Cefotaxime showed no inhibition in the growth of E. coli (GN9, IB9), K. pneumoniae (KP7) and A. baumannii (AB13775). However, the same antibiotic showed an increase in fold area when combined with the extracts of LU11 and LS6 (Table 3) .
Minimum inhibitory concentration
The MIC value of the extracts correlated with the well-diffusion assay of bacteriocin activity (Table 4 ). The MIC of the bacteriocin extract of LU11 against E. coli MTCC 730 was 6.66 mg/mL, which was recorded as the lowest MIC value (Table 4 ). For the clinical isolates E. coli (GN9, IB9), K. pneumoniae (KP7) and A. baumannii (AB13775), the MIC was found to be 20.33, 26.66, 13.33 and 16.66 mg/mL, respectively, with the bacteriocin extract of LU11 (Table 4 ). The MIC of LS6 extract was 20 mg/mL against E. coli MTCC 730 and 22.66, 18, 10 and 33.33 mg/mL against A. baumannii AB13775, K. pneumoniae KP7 and E. coli (GN9, IB9), respectively. The bacteriocin extract from the isolate LU11 showed lower MIC values against E. coli MTCC 730 and the clinical pathogens A. baumannii AB13775 as well as E. coli IB9 in comparison with LS6 (Table 4 ). 
þþþ Inhibitory zone > 10 mm; þþ inhibitory zone 7e10 mm; þ inhibitory zone 5e7 mm; À no inhibitory zone. LAB ¼ lactic acid bacteria. Bacteriocins from LAB inhibit b-lactamase-producing pathogens 3.4. Identification of potential bacteriocin-producing LAB All the 11 potent bacteriocin-producing bacterial isolates were gram positive and catalase negative. Nine isolates were rod shaped and two were found to be cocci (Table 5 ). The isolates were characterised using 16S rRNA gene sequencing approach ( Figure S3 ) and BLAST programme performed against the database at EzTaxon server to identify the nearest phylogenetic neighbours. Among the 11 bacteriocinogenic LAB isolates, Lactobacillus was the most predominant representing 72.7% of the isolates. Pediococcus comprised 18.18% of the isolates, whereas Enterococcus comprised 9.09% of the isolates. The bacterial isolates were found to be the closest homolog of Lactobacillus plantarum with a similarity of 99.80% (LS5, KB10, LS8, LS6), Lactobacillus fermentum with a similarity of 98.52% (GS4), Pediococcus pentosaceus with a similarity of 99.32% (LS9, LU11), Lactobacillus casei with a similarity of 98.54% (KTP1), Lactobacillus brevis with a similarity of 99.78% (KTP1, KTP5) and Enterococcus sp. with a similarity of 97.74% (LS3) (Table 5; Figure 4 ).
Discussion
Because of the broad spectrum of activity against bacteria and very low toxicity to humans, b-lactam group of antibiotics are widely used in the hospital settings for the treatment of human diseases. These antibiotics are rendered ineffective by bacteria producing b-lactamases, an enzyme capable of hydrolysing the blactam ring. Bacteriocins from LAB have huge potential to serve as food preservatives and also as next generation antibiotics, which can be used to target the MDR pathogens (Perez et al. 2014) . Thus, the potential bacteriocin effective against these b-lactamase-producing organisms could serve as an alternative option for the treatment of hospitalized and community-based patients. In this study, LAB that are inherent to the traditionally fermented foods were isolated and explored for their potential to produce bacteriocins, which could inhibit the growth of b-lactamase-producing clinical isolates of gram-negative bacilli.
The study revealed 13% (11 of 84) of the isolates producing bacteriocin-like substances which could inhibit the growth of the indicator organisms. Sezer and Güven (2009) reported that only 35 LAB isolates exhibited antibacterial activity from a total of 12,700 LAB isolated from milk and meat products. Sharpe (2009) reported detection of 8.7% bacteriocin-producing strains among 92 LAB isolated from fresh cut vegetable products. In the present study, it was observed that all the eleven isolates had inhibited the growth of E. coli, K. pneumoniae and B. cereus, which corroborates to earlier reports (Mohankumar 2011; Rapsang et al. 2011 Rapsang et al. , 2013 . Difference in antimicrobial activity of the different isolates could be due to the different pathway for the production of lactic acid by homofermentative and heterofermentative lactobacilli (Tejero Sarinena et al. 2012) . Physio-chemical characterization of the cell-free supernatant was carried out by treating the bacteriocin produced by the LAB with different enzymes and also by subjecting them to different temperature and pH ranges. Treatment of the bacteriocin with various proteolytic enzymes (trypsin, proteinase K, pronase E) resulted in the loss of the antibacterial activity. This indicated the proteinaceous nature of the compounds. Same set of proteolytic enzymes also inactivated nisin (Hurst 1981) and similar results have also been reported by Gaji c et al. (1999) . Bacteriocins are relatively heat stable molecules. The activity of the cell- free supernatant was retained at various pH ranges and was not affected by heat treatment at 80 C for 60 min. The work carried out by Lade et al. (2006) also reported that bacteriocin isolates were stable at 100 C for 10 min and bacteriocin of Lactobacillus lactis was stable in acidic condition. Sarika et al. (2010) also reported heat and pH stability of bacteriocin Lactobacillus rhamnosus.
Because of their potential use as antimicrobial agents for improving the safety of food products, there is an increasing interest in the research of antimicrobial peptides (bacteriocins and bacteriocin-like compounds) produced by LAB (Yildirim et al. 1999) . Apart from its inhibition spectrum, technological properties like heat and wide range of pH stability provide the bacteriocin with an application potential as a biopreservative (Abo-Amer, 2007) . Although biochemically and genetically many bacteriocins have been characterized, several aspects of these compounds are still unknown (Cleveland et al. 2001) , this explains why till date nisin, approved by the Food and Drug Administration, is the only purified bacteriocin widely used as a food preservative.
The present study also explored the antibacterial spectrum of the LAB isolates against MDR bacterial species. There are reports on the efficacy of the commercially available bacteriocin, nisin against pathogenic strains of MDR S. aureus, pneumococci and MRSA (Severina et al. 1998) . The active supernatants of the potential isolates L. plantarum LS6 and P. pentosaceus LU11 showed good inhibitory effects against the bacteria harbouring b-lactamases.
Bacteriocins from these isolates had a broader host range against the clinical isolates. Among the nosocomial strains used in the study, K. pneumoniae and A. baumannii have proven to be sensitive targets of the bacteriocin extracted from L. plantarum LS6 and P. pentosaceus LU11. Bacteriocin extract from these isolates also showed good inhibition activity and MIC against isolates of E. coli, producing extended-spectrum b-lactamases and metallo-b-lactamases. The MIC value of P. pentosaceus crude extract against the gram-negative nosocomial isolate K. pneumoniae and A. baumannii was recorded to be lower than the MIC value obtained for the extract of L. plantarum. Jang et al. (2015) studied the activity of P. pentosaceus T1 against Listeria monocytogenes and reported that the MIC of this pediocin isoform (20 mg/mL) is lower than that of nisin.
L. plantarum strains produce a broad range of bacteriocins such as ST28MS, ST26MS, bacST202Ch, bacST216Ch, ST71KS, plantaricin B, D, K, MG, JKZJ008, etc (Dinev et al. 2017) . According to previous studies, it is reported that L. plantarum is active against many Gramnegative pathogens, food spoilage microorganisms and various MDR (Dinev et al. 2017) . Zang et al. (2016) reported that L. plantarum ZDY 2013 significantly inhibited the adhesion of enterotoxin-producing and pathogenic strains of B. cereus on intentional epithelial cells by inhibition, competition and displacement. The antimicrobial activity of LAB and L. plantarum can be explained by three mechanisms: the production of bacteriocins; the yield of organic acids, ethanol, carbon dioxide and hydrogen peroxide; and the competition of nutrients (Magnusson et al. 2003) . Our results showed that the strain of L. plantarum has potential to produce antibacterial substances, which can be viable alternative to antibiotics to treat the pandrug-resistant organisms. Kumar et al. (2016) also concluded that L. plantarum strains which are effective against a variety of bacterial pathogens including MRSA and MDR enteroaggregative E. coli can serve as alternative therapeutic agents against the corresponding infections in humans and animals.
Similar to L. plantarum, Pediococcus cultures are evident as protective cultures against common food spoilage bacteria and pathogens. P. pentosaceus is one of the main species used in pediocin production, fermentation processes as starter culture and probiotic supplements for humans and animals (Porto et al. 2017) .
Recently, several studies have demonstrated pediocin production from different P. pentosaceus strains such as P. pentosaceus CB4, R38, OZF, NDCD273 (Devi and Halami 2011; Osmanagaoglu et al. 2013; Simha et al. 2012) . In a study performed by Yin et al. 2003 , it was reported that pediocin from P. pentosaceus inhibited the growth of various Gram-negative microorganisms.
Based on the varied investigations, P. pentosaceus and L. plantarum can be considered as important LAB species and the purified form of their bacteriocins can be explored as potent antibacterial candidate for the treatment of nosocomial infections.
One of the greatest concerns that mankind is facing today is the rising problem of MDR pathogens and the rapidly decreasing spectrum of antibiotics to control these pathogens. In the present study, it was observed that the bacteriocin from the LAB alone and in combination with polymyxin B, tigecycline, imipenem and cefotaxime had an inhibitory activity on MDR strains of bacteria. Although these antimicrobials cannot replace the widely used antibiotics, they may serve as valuable antibiotic complements. Traditionally fermented products harbouring a range of probiotics LAB is a rich gene pool of organisms providing such complements. To take advantage of these new antimicrobials in synergistic combination therapy, it will be essential to determine the best possible ratio and dosing treatment and to study the mechanism of their activity exploring metabolomic technologies.
